XERS Live signals | Maximize Profits with Getagraph.com

SELL 103416 min ago

@ $2.97

Issued: 14 Feb 2024 @ 09:30

Return: -42.74%

Previous signal: Feb 13 - 12:28

Previous signal: Buy

Return: 2.92 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology...

Stats
Today's Volume	863 165
Average Volume	1.91M
Market Cap	238.77M
EPS	$0 ( 2024-03-06 )
Next earnings date	( $-0.120 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.78
ATR14	$0.00400 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Sherman Jeffrey W	Buy	6 502	Common Stock
2024-03-15	Kong Garheng	Buy	6 474	Common Stock
2024-03-15	Johnson John	Buy	89 571	Common Stock
2024-03-18	Johnson John	Buy	215 600	Common Stock
2024-03-18	Johnson John	Sell	215 600	Stock Option (Right to Buy)

INSIDER POWER
92.72
Last 99 transactions
Buy: 12 203 668 \| Sell: 238 056

Volume Correlation

Long: 0.04 (neutral)

Short: 0.75 (moderate)

Signal:(44.148) Neutral

Xeris Pharmaceuticals Inc Correlation

10 Most Positive Correlations
MTSL	0.806
DBDR	0.802

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Xeris Pharmaceuticals Inc Correlation - Currency/Commodity

0.09
( neutral )

0.34
( neutral )

0.00
( neutral )

0.15
( neutral )

Xeris Pharmaceuticals Inc Financials

Annual	2024
Revenue:	$163.91M
Gross Profit:	$124.43M (75.91 %)
EPS:	$-0.450

FY	2024
Revenue:	$163.91M
Gross Profit:	$124.43M (75.91 %)
EPS:	$-0.450

FY	2023
Revenue:	$110.25M
Gross Profit:	$87.61M (79.47 %)
EPS:	$-0.700

FY	2022
Revenue:	$110.25M
Gross Profit:	$87.61M (79.47 %)
EPS:	$-1.200

Financial Reports:

No articles found.

Xeris Pharmaceuticals Inc

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.